IPN Ipsen SA

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024

PARIS, FRANCE, 28 May 2024 - In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014, the Delegated Regulation No 2016/1052 of 8 March 2016, and the General Regulation of the French Autorité des Marchés Financiers (AMF), the present description aims to describe the objectives and characteristics of the repurchase by the Company of its own shares, that it could in theory implement. This repurchase is proposed to the authorization of today’s (28 May 2024) Annual General Meeting in its 15th resolution. The preliminary notice of meeting, including the agenda and the draft resolutions, has been published in the Bulletin des Annonces Légales Obligatoires (BALO) on 17 April 2024 and the notice of meeting in the BALO on 6 May 2024.

Date of the Annual General Meeting called to authorize the repurchase of IPSEN’s own shares

The authorization for the Company to repurchase its own shares is proposed to the Annual General Meeting today, 28 May 2024, in its 15th resolution.

Characteristics of the share repurchase program proposed to the approval of the Annual General Meeting

Objectives

The objectives of the share repurchase program to be proposed at today’s (28 May 2024) Annual General Meeting are to:

  • stimulate the secondary market or ensure the liquidity of Ipsen shares through the activities of an investment service provider in the form of a liquidity agreement compliant with the practices authorized under the regulations, it being specified that within this context, the number of shares used to calculate the below-mentioned limit corresponds to the number of shares purchased, decreased by the number of shares sold;
  • retain the purchased shares and subsequently deliver them for an exchange in the context of a merger, demerger or contribution or a payment related to possible external growth transactions;
  • ensure the hedging of stock option plans and/or free shares plans (or similar plans) in favor of Group employees and/or corporate officers (including affiliated companies or economic interest groups) as well as all allocations of shares under a Company or Group savings plan (or a similar plan), as part of the sharing of the Company’s profits and/or all other forms of allocation of shares to Group employees and/or corporate officers;
  • ensure the coverage of negotiable securities giving rights to the allocation of Company shares in accordance with the regulations in force;
  • possibly cancel acquired shares, in accordance with the authorization granted or to be granted by the Extraordinary Annual General Meeting.

Characteristics:

These share purchases, sales, transfers or exchanges may be carried out by all means, including on the market or off-market, by multilateral trading facilities or through systematic internalizers, over-the-counter, including through the acquisition or sale of blocks of securities, and at any times as the Board shall see fit.

The Company would reserve the right to use options or derivative instruments in accordance with applicable regulations. The transactions could not be carried out during a public offer period initiated by a third party for the Company’s shares and until the end of the offer period.

Maximum amount of share capital that could be acquired, maximum number and characteristics of the corresponding shares, maximum repurchase price

The maximum percentage of shares that might be repurchased pursuant to the authorization proposed to the Annual General Meeting on 28 May 2024 is set, in accordance with Articles L.22-10-62 et seq and L.225-210 of the French Commercial Code, at a possible repurchase within the limit of a maximum number of shares that may not represent more than 10 % of the total number of shares comprising the share capital (i.e., 8,381,452 shares as of today), specifying that this limit is considered as of the date of the repurchases, adjusted, if applicable, to take into account possible share capital increases or reduction that may occur during the period covered by the program. The number of shares taken into account for the calculation of this limit corresponds to the number of shares repurchased, deducted by the number of shares sold during the program in connection with the liquidity purpose.

Since the Company may not hold more than 10% of its share capital, and considering the number of shares already held amounting, on 30 April 2024, to 1,109,181 (representing about 1.32% of the share capital), the maximum theoretical number of shares that may be repurchased would be 7,272,271, representing about 8.68% of the share capital, unless transfers or cancellations of shares already held.

The maximum purchase price proposed to today’s (28 May 2024) Annual General Meeting is set at €200 per share. Consequently, the theoretical maximum amount likely to be devoted to these repurchase would be set by the Annual General Meeting at €1,676,290,400 based on a number of 83,814,526 shares.

Duration

In accordance with the 15th resolution proposed to today’s (28 May 2024) General Meeting, any repurchase of shares may be implemented within a period of 18 months following the date of this General Meeting, i.e. until 27 November 2025.

This authorization will cancel and supersede the previous authorization granted by the General Meeting on 31 May 2023 in its 15th ordinary resolution.

The present publication is available on the Company’s website ().

Attachment



EN
28/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE

Cabometyx® approved in the EU for previously treated advanced neuroend...

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2Approval based on pivotal CABINET Phase III trial which demonstrated a 77% and 62% reduction in the risk of disease progression or death versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumors, respectively3,4 PARIS, FRANCE, 24 July...

 PRESS RELEASE

Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines a...

Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines avancées précédemment traitées Cabometyx® est le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines non résécables ou métastatiques précédemment traitées, indépendamment de la localisation de la tumeur, de sa gravité et de l’administration ou non d’un traitement systémique auparavant, autre qu’un traitement par analogue de la somatostatine1,2.Approbation basée sur l’essai pivotal de Phase III CABINET qui a démontré une réduction de 77 % et 62 % du risque de progression...

 PRESS RELEASE

Ipsen announces changes to its Executive Committee

Ipsen announces changes to its Executive Committee PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product OfficerAndreas Gerber is appointed to EVP, Head of InternationalCaroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen’s Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the Internat...

 PRESS RELEASE

Ipsen annonce des changements au sein de son Comité Exécutif

Ipsen annonce des changements au sein de son Comité Exécutif PARIS, FRANCE, 23 juillet 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), groupe biopharmaceutique mondial de spécialité, annonce aujourd'hui les changements suivants au sein de son Comité Exécutif : Mari Scheiffele est nommée Vice-Présidente Exécutive, Directrice des Produits.Andreas Gerber est nommé Vice-Président Exécutif, Directeur International.Caroline Sitbon est nommée Vice-Présidente Exécutive, Directrice Juridique. Mari, Andreas et Caroline reporteront à David Loew, Directeur Général d'Ipsen, à compter du 1er septembre 2025. ...

 PRESS RELEASE

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025 Aggregated presentation by day and by market Statement of transactions in own shares from July 14th to July 18th 2025        Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1114/07/2025FR0010259150 240 105,775AQEUIPSEN549300M6SGDPB4Z94P1114/07/2025FR0010259150 706 105,86459CCXEIPSEN549300M6SGDPB4Z94P1114/07/2025FR00...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch